Literature DB >> 28736335

TFOS DEWS II Definition and Classification Report.

Jennifer P Craig1, Kelly K Nichols2, Esen K Akpek3, Barbara Caffery4, Harminder S Dua5, Choun-Ki Joo6, Zuguo Liu7, J Daniel Nelson8, Jason J Nichols2, Kazuo Tsubota9, Fiona Stapleton10.   

Abstract

The goals of the TFOS DEWS II Definition and Classification Subcommittee were to create an evidence-based definition and a contemporary classification system for dry eye disease (DED). The new definition recognizes the multifactorial nature of dry eye as a disease where loss of homeostasis of the tear film is the central pathophysiological concept. Ocular symptoms, as a broader term that encompasses reports of discomfort or visual disturbance, feature in the definition and the key etiologies of tear film instability, hyperosmolarity, and ocular surface inflammation and damage were determined to be important for inclusion in the definition. In the light of new data, neurosensory abnormalities were also included in the definition for the first time. In the classification of DED, recent evidence supports a scheme based on the pathophysiology where aqueous deficient and evaporative dry eye exist as a continuum, such that elements of each are considered in diagnosis and management. Central to the scheme is a positive diagnosis of DED with signs and symptoms, and this is directed towards management to restore homeostasis. The scheme also allows consideration of various related manifestations, such as non-obvious disease involving ocular surface signs without related symptoms, including neurotrophic conditions where dysfunctional sensation exists, and cases where symptoms exist without demonstrable ocular surface signs, including neuropathic pain. This approach is not intended to override clinical assessment and judgment but should prove helpful in guiding clinical management and research.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aqueous deficient; Classification; Definition; Dry eye disease; Evaporative; Mechanism

Mesh:

Year:  2017        PMID: 28736335     DOI: 10.1016/j.jtos.2017.05.008

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  512 in total

1.  Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease.

Authors:  Agnė Žiniauskaitė; Symantas Ragauskas; Anita K Ghosh; Rubina Thapa; Anne E Roessler; Peter Koulen; Giedrius Kalesnykas; Jenni J Hakkarainen; Simon Kaja
Journal:  Ocul Surf       Date:  2019-02-23       Impact factor: 5.033

2.  Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics.

Authors:  Penny A Asbell; Maureen G Maguire; Ellen Peskin; Vatinee Y Bunya; Eric J Kuklinski
Journal:  Contemp Clin Trials       Date:  2018-06-06       Impact factor: 2.226

3.  The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease.

Authors:  Munira Hussain; Roni M Shtein; Maxwell Pistilli; Maureen G Maguire; Marko Oydanich; Penny A Asbell
Journal:  Ocul Surf       Date:  2019-08-16       Impact factor: 5.033

4.  Comprehensive Clinical, Diagnostic, and Advanced Imaging Characterization of the Ocular Surface in Spontaneous Aqueous Deficient Dry Eye Disease in Dogs.

Authors:  Brian C Leonard; Kathleen A Stewart; Gillian C Shaw; Alyssa L Hoehn; Amelia A Stanley; Christopher J Murphy; Sara M Thomasy
Journal:  Cornea       Date:  2019-12       Impact factor: 2.651

5.  [Diagnosis of dry eye disease].

Authors:  C Jacobi; E M Messmer
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

6.  n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.

Authors:  Penny A Asbell; Maureen G Maguire; Maxwell Pistilli; Gui-shuang Ying; Loretta B Szczotka-Flynn; David R Hardten; Meng C Lin; Roni M Shtein
Journal:  N Engl J Med       Date:  2018-04-13       Impact factor: 91.245

7.  Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease.

Authors:  Rohan Bir Singh; Ann Yung; Giulia Coco; Shruti Sinha; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2020-07-30       Impact factor: 5.033

8.  Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Authors:  Valerie Yu; Dhruva Bhattacharya; Andrew Webster; Aditi Bauskar; Charles Flowers; Martin Heur; Shravan K Chintala; Tatsuo Itakura; Mark R Wilson; Joseph T Barr; Shinwu Jeong; Mingwu Wang; M Elizabeth Fini
Journal:  Ocul Surf       Date:  2018-08-02       Impact factor: 5.033

Review 9.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

10.  Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction.

Authors:  José-María Sánchez-González; Concepción De-Hita-Cantalejo; María Carmen Sánchez-González
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.